In conclusion, the therapeutic effectiveness of BoNT-A in migraine prevention may be explained by the simultaneous lowering of CGRP release, sensitivity to molecules that activate nociceptive meningeal C-afferents via TRPV1 and TRPA1, and pre-existing inflammation. The gene discussed is TRPV1; the disease is migraine disorder.